Titration is the practice of starting a drug at a low dose and increasing in steps to reach the target maintenance dose. For GLP-1s, this is critical because GI side effects (nausea, vomiting, diarrhea) are dose-dependent. Wegovy: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks. Skipping titration triples discontinuation rates from intolerable nausea.
Related terms
- Semaglutide
- GLP-1 receptor agonist; active ingredient in Wegovy, Ozempic, and Rybelsus.
- Tirzepatide
- Dual GIP/GLP-1 receptor agonist; active ingredient in Mounjaro and Zepbound.